Company Description

Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases.

Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (“DMD”).

Satellos has generated evidence in preclinical models of DMD to support its hypothesis that correcting muscle stem cell polarity through treatment with SAT-3247 has the potential to restore skeletal muscle regeneration, thereby enhancing repair and increasing muscle strength.

SAT-3247 is the Company’s lead drug candidate. SAT-3247 is currently in clinical development in two clinical trials.

Additionally, Satellos continues to leverage its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases where deficits in muscle regeneration may occur that are amenable to therapeutic intervention for future development.